Fluoxetine

Generic Name
Fluoxetine
Brand Names
Prozac, Sarafem, Symbyax
Drug Type
Small Molecule
Chemical Formula
C17H18F3NO
CAS Number
54910-89-3
Unique Ingredient Identifier
01K63SUP8D
Background

Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.

Indication

Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present. Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar ...

Associated Conditions
Alcohol Dependency, Anorexia Nervosa (AN), Bulimia Nervosa, Cataplexy, Depression, Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Myoclonus, Obesity, Obsessive Compulsive Disorder (OCD), Panic Disorder With Agoraphobia, Panic disorder without agoraphobia, Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD)
Associated Therapies
Maintenance therapy
Clinical Trials
Related News

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

First Posted Date
2021-09-13
Last Posted Date
2024-10-28
Lead Sponsor
University of Oxford
Target Recruit Count
3800
Registration Number
NCT05041907
Locations
🇳🇵

Sukraraj Tropical & Infectious Disease Hospital, Kathmandu, Nepal

🇧🇷

Universidade Federal de Minas Gerais, Minas Gerais, Brazil

🇱🇦

Laos-Oxford-Mahosot Wellcome Trust Research Unit, Vientiane, Lao People's Democratic Republic

and more 4 locations

Study of Dextromethorphan in OCD and Related Disorders

First Posted Date
2021-05-24
Last Posted Date
2024-04-26
Lead Sponsor
Stanford University
Target Recruit Count
60
Registration Number
NCT04899687
Locations
🇺🇸

Stanford University, Stanford, California, United States

Fluoxetine Mitigation Mental Health Study for Patients With Musculoskeletal Trauma

Phase 2
Active, not recruiting
Conditions
Musculoskeletal Injury
Interventions
Drug: Fluoxetine
Drug: Calcium
First Posted Date
2021-04-20
Last Posted Date
2024-10-26
Lead Sponsor
University of Florida
Target Recruit Count
150
Registration Number
NCT04850222
Locations
🇺🇸

University of Florida, Gainesville, Florida, United States

Fluoxetine vs CBT in Childhood Anxiety Disorders

First Posted Date
2021-02-18
Last Posted Date
2024-10-29
Lead Sponsor
Children's Hospital Los Angeles
Target Recruit Count
316
Registration Number
NCT04760275
Locations
🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

The Safety and Efficacy of Fluoxetine for Refractory Primary Mono-symptomatic Nocturnal Enuresis in Children

First Posted Date
2020-12-19
Last Posted Date
2020-12-19
Lead Sponsor
Mansoura University
Target Recruit Count
100
Registration Number
NCT04676139
Locations
🇪🇬

Mansoura urology and nephrology center, Mansoura, Dakahlia, Egypt

Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)

Early Phase 1
Withdrawn
Conditions
Covid19
Interventions
Drug: Placebo
Drug: Fluoxetine
First Posted Date
2020-09-30
Last Posted Date
2020-12-24
Lead Sponsor
Milton S. Hershey Medical Center
Registration Number
NCT04570449
Locations
🇺🇸

Milton S. Hershey Medical Center Clinical Research Center, Hershey, Pennsylvania, United States

Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea

First Posted Date
2020-06-24
Last Posted Date
2024-12-09
Lead Sponsor
Pfizer
Target Recruit Count
370212
Registration Number
NCT04446039
Locations
🇰🇷

Pfizer, Seoul, Korea, Republic of

Fluoxetine to Reduce Intubation and Death After COVID19 Infection

Phase 4
Completed
Conditions
Cytokine Storm
COVID-19
Interventions
Drug: Fluoxetine
First Posted Date
2020-05-06
Last Posted Date
2024-06-07
Lead Sponsor
University of Toledo Health Science Campus
Target Recruit Count
16
Registration Number
NCT04377308
Locations
🇺🇸

University of Toledo, Toledo, Ohio, United States

The Activation on Prefrontal Cortex With Acupuncture and Moxibustion for Major Depressive Disorder: A Study of Functional Near Infrared Spectroscopy

First Posted Date
2020-02-17
Last Posted Date
2020-02-17
Lead Sponsor
Chengdu University of Traditional Chinese Medicine
Target Recruit Count
20
Registration Number
NCT04272476
Locations
🇨🇳

Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China

Study on the Optimal Strategy of Chinese Patients With Bulimia Nervosa After Fluoxetine Treatment

First Posted Date
2019-11-07
Last Posted Date
2021-09-16
Lead Sponsor
Shanghai Mental Health Center
Target Recruit Count
550
Registration Number
NCT04154813
Locations
🇨🇳

Shanghai Mental Health Center, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy